Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of eculizumab in relapsing neuromyelitis optica
2013-001151-12Phase 3Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jul 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of eculizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD), sponsored by Alexion Pharmaceuticals. Primary endpoint: Trial emergent adverse effects. Started Jul 2013; status: completed.
02
Drugs
eculizumab
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on 2013-001151-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001151-12.